Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Class A common stock
-
Shares outstanding
-
4,195,190
-
Total 13F shares
-
343,260
-
Share change
-
+5,415
-
Total reported value
-
$1,238,359
-
Put/Call ratio
-
5.4%
-
Price per share
-
$3.64
-
Number of holders
-
19
-
Value change
-
+$17,014
-
Number of buys
-
4
-
Number of sells
-
7
Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) as of Q1 2023
As of 31 Mar 2023,
Enlivex Therapeutics Ltd. - Class A common stock (ENLV) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
343,260 shares.
The largest 10 holders included
Compagnie Lombard Odier SCmA, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, MORGAN STANLEY, UBS Group AG, GOLDMAN SACHS GROUP INC, Susquehanna International Group Ltd., GROUP ONE TRADING, L.P., EDMOND DE ROTHSCHILD HOLDING S.A., and SIMPLEX TRADING, LLC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.